Fluifort Sciroppo 2.7g / 10ml Carbocisteina Mucolitico Tosse 6 Bustine Monodose

Syrup based on carbocysteine salt of lysine monohydrate.

Therapeutic indications

Fluifort syrup is used as a mucolytic, fluidifying agent in acute and chronic respiratory diseases.

Dosage and posology

The drug should be taken according to the following doses and methods: 1 sachet per day.

Fluifort 2.7 g / 10 ml syrup, thanks to its innovative packaging, ensures precision in dosage, hygiene, practicality and ease of intake and is particularly suitable for diseases in the acute phase for which short-term treatment is required. In consideration of the pharmacokinetic characteristics, the recommended posology can be maintained even in patients with renal and hepatic insufficiency. Duration of treatment: carbocysteine lysine salt monohydrate can also be used for prolonged periods, in this case it is advisable to follow the doctor's advice.

Overdose

The symptoms reported in case of overdose are: headache, nausea, vomiting, diarrhea, gastralgia, skin reactions, alteration of the sensory systems. There is no specific antidote; it is advisable to induce vomiting and possibly perform gastric lavage followed by specific supportive therapy.

Contraindications

• Hypersensitivity to the active substance or to any of the excipients
• Gastroduodenal ulcer.
• Pregnancy and breastfeeding.
• The drug is contraindicated in pediatric patients under 11 years of age.

Side effects

Side effects that can occur with Fluifort, classified by system organ (SOC), are as follows:

• Skin, subcutaneous tissue disorders: skin rash, urticaria, erythema, exanthema, bullous rash / erythema, pruritus, angioedema, dermatitis.
• Gastrointestinal disorders: abdominal pain, nausea, vomiting, diarrhea.
• Nervous system disorders: dizziness.
• Respiratory, thoracic and mediastinal disorders: dyspnoea.
• Vascular disorders: redness

Pregnancy and breastfeeding

Although the active substance is neither teratogenic nor mutagenic and has not shown negative effects on reproductive function in animals, Fluifort should not be administered during pregnancy. Since no data are available regarding the passage of carbocysteine lysine salt monohydrate into breast milk, use during lactation is contraindicated.

Special warnings

There are no known phenomena of addiction or dependence. The medicine contains methyl para-hydroxybenzoate and propyl para-hydroxybenzoate, which are known to cause urticaria. In general, para-hydroxybenzoates can cause delayed reactions, such as contact dermatitis and rarely immediate reactions with manifestation of urticaria and bronchospasm.

The medicine contains sorbitol, patients with rare hereditary problems of fructose intolerance should not take this medicine. Fluifort 2.7 g / 10 ml syrup does not affect low-calorie or controlled diets and can also be administered to diabetic patients. Fluifort 2.7 g / 10 ml syrup does not contain aspartame; therefore it can be administered to patients with phenylketonuria. Fluifort 2.7 g / 10 ml syrup does not contain gluten; therefore it can be administered to patients with celiac disease. Open the sachet following the dotted line and ingest its contents.

Expiry and retention

Check the expiration date indicated on the package. The expiry date indicated on the package refers to the product in intact packaging, correctly stored. Store at a temperature below 25 ° C. If stored correctly, any change in color of the preparation does not affect the therapeutic activity of the specialty which remains valid until the expiry date indicated.

Warning : do not use the medicine after the expiry date indicated on the package.

Composition

One sachet of Fluifort Syrup contains:

Active principle

Carbocysteine lysine salt monohydrate equal to 2.7 g of carbocysteine lysine salt

Excipients

Sorbitol (70% solution); xylitol; ammonium glycyrrhizinate; carmellose sodium; glycerol; cherry flavor; methyl para-hydroxybenzoate; propyl para-hydroxybenzoate; purified water.